BCR-ABL/SRC/p38 kinase inhibitors (University Of Science & Technology Of China/Hefei Co-Source Pharmaceuticals/Chinese Academy of Sciences)

N/A

Report date: 2025/01/26 18:26:30
NME

Base Information

Drug NameBCR-ABL/SRC/p38 kinase inhibitors (University Of Science & Technology Of China/Hefei Co-Source Pharmaceuticals/Chinese Academy of Sciences)
Drug Alias NameCHMFL-ABL-053
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP38 α mitogen-activated protein kinase inhibitorsTyrosine-protein kinase SRC inhibitorsBcr-Abl tyrosine kinase inhibitors
TargetsTyrosine-protein kinase SRCBcr-Abl tyrosine kinaseP38 α mitogen-activated protein kinase
Therapy Area/IndicationsLeukemia, Myelogenous, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesUniversity Of Science And Technology Of China
China Registration ClassN/A

Develop Information

Active CompaniesChinese Academy Of SciencesHefei Cosource Medicine TechnologyUniversity Of Science And Technology Of China
Inactive CompaniesN/A
Active IndicationsLeukemia, Myelogenous, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A